Regeneron Pharmaceuticals, Inc. vs Merck & Company, Inc. — Stock Comparison
Q·Score Breakdown
8
Buy
Overall
7.3
Buy
Quality
Health
Growth
Valuation
Sentiment
REGN
Clean balance sheet with low leverage (0.1× debt-to-equity).
MRK
High-quality business with 37% return on equity and 28% profit margins.
⚠ earnings contracting 19% year-over-year.
Analyst Consensus
BUY
Target $877.73 (+24.7%)
28 analysts
BUY
Target $129.74 (+17.4%)
27 analysts
Fundamentals
REGN
MRK
17.2×
Trailing P/E
15.2×
13.3×
Forward P/E
11.4×
29.6%
Profit Margin
28.1%
44.6%
Gross Margin
77.2%
14.5%
ROE
36.9%
19.0%
Revenue Growth
5.0%
-7.2%
Earnings Growth
-19.3%
0.40
Beta
0.28
—
Price / Book
—
$73.8B
Market Cap
$272.9B
$476 – $821
52-Week Range
$73 – $125
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load.